NOX 14.3% 8.0¢ noxopharm limited

As you seem determined to be pedantic, let’s look at your...

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    As you seem determined to be pedantic, let’s look at your objections:
    1. You objected to my statement that “Yesterday’s announcement said that the first patient had been treated, so we know that there were no serious adverse reactions”. This is surely a true statement – there was no serious reaction when Veyonda was first administered, otherwise the trial would have been halted. Whether serious events occur later in the trial remains to be seen.
    2. I wrote that “Having failed prior treatment, any improvement in their WHO score should be attributable to Veyonda”. I did not say that a response must be attributable to Veyonda, but I respectfully suggest that Noxopharm would have done everything within their control in the protocol design to avoid data contamination.

    I am certainly not privy to confidential trial data. My objective here is to provide a succinct summary for readers who do not have the time to research Noxopharm.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.